Candel Therapeutics reported a decrease in operating expenses by $2.8 million compared to Q3 2023, driven by cost management and restructuring.

Indaptus Therapeutics reported a 26% decrease in operating expenses for Q3 2024, driven by the completion of certain manufacturing processes for Decoy20.

Cellectar Biosciences is progressing its lead therapeutic, iopofosine I 131, through clinical trials targeting relapsed/refractory Waldenstrom’s macroglobulinemia (WM) and multiple myeloma (MM).

A class action lawsuit has been filed against Humacyte, Inc. for allegedly misleading investors regarding its manufacturing practices and the FDA review of its Biologic License Application (BLA).

Kura Oncology is focusing on precision medicines for cancer, targeting genetic mutations to improve treatment efficacy and safety.

Adverum's Ixo-vec demonstrates maintenance of visual and anatomic outcomes in wet AMD patients, reducing the need for anti-VEGF injections.

UNITY Biotechnology's UBX1325 (foselutoclax) targets senescent cells in diabetic macular edema (DME), offering a novel approach to address limitations of current anti-VEGF therapies.

Nuvectis Pharma reported a net loss of $4.2 million for the quarter ended September 30, 2024, a decrease of $1.7 million compared to the same period in 2023.

Dogwood Therapeutics reported no revenue for Q3 2024 but highlighted ongoing clinical development in pain and fatigue-related disorders.

Kiromic BioPharma's Deltacel-01 demonstrates a 6-month median Progression Free Survival (PFS) in early clinical trials, with the longest PFS observed at 10 months.

SpringWorks Therapeutics' OGSIVEO generated significant revenue, with $49.3 million in Q3 2024 and $130.0 million for the first nine months, following its FDA approval for desmoid tumors.

Vera Therapeutics received FDA Breakthrough Therapy Designation for atacicept, a potential treatment for IgA nephropathy (IgAN).

Protara Therapeutics' TARA-002 shows promise in NMIBC treatment, with ADVANCED-2 trial results expected in Q4 2024, and positive interim data in Lymphatic Malformations.

Aura Biosciences reports progress in Phase 3 trial for choroidal melanoma with bel-sar, showing an 80% tumor control rate in Phase 2 among Phase 3-eligible patients.

Alterity Therapeutics' ATH-434 demonstrated statistically significant slowing of clinical progression in early-stage multiple system atrophy (MSA) patients.

FibroGen anticipates top-line data from Phase 3 trials of pamrevlumab in metastatic and locally-advanced pancreatic cancer, addressing a significant unmet need.

Reproxalap, a novel small molecule drug, inhibits RASP, which are elevated in inflammatory diseases, offering a new approach to reduce ocular inflammation in dry eye disease.

Kalaris Therapeutics and AlloVir have finalized their merger, with the combined entity operating under the Kalaris name and trading on Nasdaq as KLRS, led by CEO Andrew Oxtoby.

Sagimet Biosciences' denifanstat received FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate to advanced liver fibrosis, based on positive Phase 2b trial data.

BioMx completed patient enrollment for its Phase 2 trial of BX201 for Diabetic Foot Osteomyelitis (DFO), with topline results expected in Q1 2025.